A Single Immunization with MVA Expressing GnGc Glycoproteins Promotes Epitope-specific CD8+-T Cell Activation and Protects Immune-competent Mice against a Lethal RVFV Infection

PLoS Neglected Tropical Diseases

Volumn 7, Issue 7, 2013, Pages

  López Gil, Elena ^a   Lorenzo, Gema ^a   Hevia, Esther ^a   Borrego, Belén ^a   Eiden, Martin ^b   Groschup, Martin ^b   Gilbert, Sarah C ^c   Brun, Alejandro ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^b FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DNA VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; RMVA GN GC VACCINE; RMVA N VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIFT VALLEY FEVER; SINGLE DRUG DOSE; VACCINATION; WESTERN BLOTTING;

EID: 84880786942     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002309     Document Type: Article

References (56)

1. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J, (2010) Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 41: 61.
2. Linthicum KJ, Davies FG, Kairo A, Bailey CL, (1985) Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an inter-epizootic period in Kenya. J Hyg (Lond) 95: 197-209.
3. Gear J, De Meillon B, Le Roux AF, Kofsky R, Innes RR, et al. (1955) Rift valley fever in South Africa; a study of the 1953 outbreak in the Orange Free State, with special reference to the vectors and possible reservoir hosts. S Afr Med J 29: 514-518.
4. Abdel-Wahab KS, El Baz LM, El-Tayeb EM, Omar H, Ossman MA, et al. (1978) Rift Valley Fever virus infections in Egypt: Pathological and virological findings in man. Trans R Soc Trop Med Hyg 72: 392-396.
5. Saluzzo JF, Digoutte JP, Chartier C, Martinez D, Bada R, (1987) Focus of Rift Valley fever virus transmission in southern Mauritania. Lancet 1: 504.
6. Sall AA, De AZPM, Vialat P, Sene OK, Bouloy M, (1998) Origin of 1997-98 Rift Valley fever outbreak in East Africa. Lancet 352: 1596-1597.
7. Rift Valley fever outbreak-Kenya, November 2006-January 2007. MMWR Morb Mortal Wkly Rep 56: 73-76.
8. Munyua P, Murithi RM, Wainwright S, Githinji J, Hightower A, et al. (2010) Rift Valley fever outbreak in livestock in Kenya, 2006-2007. Am J Trop Med Hyg 83: 58-64.
9. Ahmad K, (2000) More deaths from Rift Valley fever in Saudi Arabia and Yemen. Lancet 356: 1422.
10. Outbreak news. Rift Valley fever, Madagascar. Wkly Epidemiol Rec 83: 157.
11. Sissoko D, Giry C, Gabrie P, Tarantola A, Pettinelli F, et al. (2009) Rift Valley fever, Mayotte, 2007-2008. Emerg Infect Dis 15: 568-570.
12. Andriamandimby SF, Randrianarivo-Solofoniaina AE, Jeanmaire EM, Ravololomanana L, Razafimanantsoa LT, et al. (2010) Rift Valley fever during rainy seasons, Madagascar, 2008 and 2009. Emerg Infect Dis 16: 963-970.
13. Roger M, Girard S, Faharoudine A, Halifa M, Bouloy M, et al. (2011) Rift valley Fever in ruminants, republic of comoros, 2009. Emerg Infect Dis 17: 1319-1320.
14. Chevalier V, Pepin M, Plee L, Lancelot R, (2010) Rift Valley fever-a threat for Europe? Euro Surveill 15: 19506.
15. Ikegami T, Makino S, (2009) Rift valley fever vaccines. Vaccine 27 Suppl 4: D69-72.
16. Boshra H, Lorenzo G, Busquets N, Brun A, (2011) Rift valley fever: recent insights into pathogenesis and prevention. J Virol 85: 6098-6105.
17. Bird BH, Nichol ST, (2012) Breaking the chain: Rift Valley fever virus control via livestock vaccination. Curr Opin Virol 2: 315-323.
18. Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, et al. (2010) Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 28: 4581-4587.
19. Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, et al. (2009) Vaccinia virus vaccines: past, present and future. Antiviral Res 84: 1-13.
20. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M, (2011) MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11: 189-217.
21. Gomez CE, Najera JL, Krupa M, Esteban M, (2008) The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8: 97-120.
22. Dunachie SJ, Walther M, Vuola JM, Webster DP, Keating SM, et al. (2006) A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24: 2850-2859.
23. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, et al. (2009) Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 7: 2.
24. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, et al. (2011) Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 16: 5539-5547.
25. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, et al. (2011) Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52: 1-7.
26. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, et al. (2010) Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 5: e13983.
27. Garcia F, Bernaldo de Quiros JC, Gomez CE, Perdiguero B, Najera JL, et al. (2011) Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine 29: 8309-8316.
28. Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, et al. (2011) Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. J Infect Dis 203: 610-619.
29. Tough DF, (2004) Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 45: 257-264.
30. Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, et al. (2006) Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 176: 4682-4689.
31. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, et al. (2006) Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24: 4657-4666.
32. Lagerqvist N, Naslund J, Lundkvist A, Bouloy M, Ahlm C, et al. (2009) Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 6: 6.
33. Wallace DB, Ellis CE, Espach A, Smith SJ, Greyling RR, et al. (2006) Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24: 7181-7189.
34. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, et al. (2010) Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 5: e9015.
35. Ledgerwood JE, Wei CJ, Hu Z, Gordon IJ, Enama ME, et al. (2011) DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 11: 916-924.
36. Lorenzo G, Martin-Folgar R, Hevia E, Boshra H, Brun A, (2010) Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens. Vaccine 28: 2937-2944.
37. Lorenzo G, Martin-Folgar R, Rodriguez F, Brun A, (2008) Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 26: 5255-5262.
38. Malin AS, Huygen K, Content J, Mackett M, Brandt L, et al. (2000) Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85. Microbes Infect 2: 1677-1685.
39. McShane H, Brookes R, Gilbert SC, Hill AV, (2001) Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69: 681-686.
40. Martin-Folgar R, Lorenzo G, Boshra H, Iglesias J, Mateos F, et al. (2010) Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization. MAbs 2: 275-284.
41. Barnard BJ, Botha MJ, (1977) An inactivated rift valley fever vaccine. J S Afr Vet Assoc 48: 45-48.
42. Bhardwaj N, Heise MT, Ross TM, (2010) Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl Trop Dis 4: e725.
43. Plebanski M, Gilbert SC, Schneider J, Hannan CM, Layton G, et al. (1998) Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 28: 4345-4355.
44. Feltquate DM, Heaney S, Webster RG, Robinson HL, (1997) Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158: 2278-2284.
45. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, et al. (1998) Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16: 439-445.
46. Schneider J, Langermans JA, Gilbert SC, Blanchard TJ, Twigg S, et al. (2001) A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 19: 4595-4602.
47. Jansen van Vuren P, Tiemessen CT, Paweska JT, (2011) Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS One 6: e25027.
48. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE,et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 186: 4331-4339.
49. Boshra H, Lorenzo G, Rodriguez F, Brun A, (2011) A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge. Vaccine 29: 4469-4475.
50. Xu W, Watts DM, Costanzo MC, Tang X, Venegas LA, et al. (2013) The nucleocapsid protein of rift valley Fever virus is a potent human CD8(+) T cell antigen and elicits memory responses. PLoS One 8: e59210.
51. Papin JF, Verardi PH, Jones LA, Monge-Navarro F, Brault AC, et al. (2011) Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci U S A 108: 14926-14931.
52. Waibler Z, Anzaghe M, Ludwig H, Akira S, Weiss S, et al. (2007) Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol 81: 12102-12110.
53. Waibler Z, Anzaghe M, Frenz T, Schwantes A, Pohlmann C, et al. (2009) Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol 83: 1563-1571.
54. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, et al. (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17: 2619-2627.
55. Pinto AK, Daffis S, Brien JD, Gainey MD, Yokoyama WM, et al. (2011) A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. PLoS Pathog 7: e1002407.
56. Dikopoulos N, Bertoletti A, Kroger A, Hauser H, Schirmbeck R, et al. (2005) Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. J Immunol 174: 99-109.